Gynecologic oncologyHumansFemaleCarcinomaOvarian EpithelialKiller Cells
Intraperitoneal infusion of stem cell-derived natural killer cells in recurrent epithelial ovarian cancer patients: Results of the phase 1 INTRO-01 trial.
Janneke S Hoogstad-van Evert, Paul K J D de Jonge, Petra L M Zusterzeel, Willemijn Hobo, Anniek B van der Waart, Hanny Fredrix, Lisanne Janssen, Maud Wuts, Lynn Bosmans, Ellen Spijkers, Merlize Djojoatmo, Veronica Castaño Rodriguez, Anna L de Goede, Bert van der Reijden, Arnold van der Meer
Published: 202610.1016/j.ygyno.2025.11.006
Abstract
INTRODUCTION: Epithelial ovarian cancer (EOC) patients exhibit a poor 5-year overall survival rate of approximately 40 %, underscoring the urgent need for innovative therapies. Allogeneic natural killer (NK) cell therapy presents a promising and safe…
Preview only. Read the full abstract at the source